Diagnosis of Burkitt lymphoma using an algorithmic approach – applicable in both resource‐poor and resource‐rich countries

Naresh, Kikkeri N.; Ibrahim, Hazem; Lazzi, Stefano; Rince, Patricia; Onorati, Monica; Ambrosio, Maria Raffaella; Bilhou-Nabéra, Chrystèle; Amen, Furrat; Reid, Alistair; Mawanda, Michael; Calbi, Valeria; Ogwang, Martin D.; Rogena, Emily; Byakika, B; Sayed, Shahin; Moshi, Emma; Mwakigonja, Amos; Raphaël, Martine; Magrath, Ian; Leoncini, Lorenzo

doi:10.1111/j.1365-2141.2011.08771.x

Cited by 58 publications

(53 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conventional procedures may need to be supplemented, and even supplanted in some instances, by diagnostic algorithms, tissue microarrays, and digital microscopy approaches suited to local conditions, as promoted by the INCTR and Sub-Saharan Africa Lymphoma Consortium. 34,93 In addition, cancers are increasingly distinguished by signature genetic aberrations and downstream molecular events. Presently, genotypic and nucleic acid amplification assays are not widely implementable in the region given inadequate existing laboratory facilities.…”

Section: Develop Conventional and Novel Diagnostics Adapted To The Sementioning

confidence: 99%

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Gopal

Wood

Lee

et al. 2012

Blood

Self Cite

View full text Add to dashboard Cite

Cancer is a leading cause of death and disability in sub-Saharan Africa and will eclipse infectious diseases within the next several decades if current trends continue. Hematologic malignancies, including non-Hodgkin lymphoma, leukemia, Hodgkin lymphoma, and multiple myeloma, account for nearly 10% of the overall cancer burden in the region, and the incidence of non-Hodgkin lymphoma and Hodgkin lymphoma is rapidly increasing as a result of HIV. Despite an increasing burden, mechanisms for diagnosing, treating, and palliating malignant hematologic disorders are inadequate. In this review, we describe the scope of the problem, including the impact of endemic infections, such as HIV, Epstein-Barr virus, malaria, and Kaposi sarcoma–associated herpesvirus. We additionally describe current limitations in hematopathology, chemotherapy, radiotherapy, hematopoietic stem cell transplantation, and supportive care and palliation. We review contemporary treatment and outcomes of hematologic malignancies in the region and outline a clinical service and research agenda, which builds on recent global health successes combating HIV and other infectious diseases. Achieving similar progress against hematologic cancers in sub-Saharan Africa will require the sustained collaboration and advocacy of the entire global cancer community.

show abstract

Section: Develop Conventional and Novel Diagnostics Adapted To The Sementioning

confidence: 99%

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Gopal

Wood

Lee

et al. 2012

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both HGAL and LMO2 lack specificity for FL, although they show stronger staining in FL compared with other types of mature B-cell lymphomas. 36 The classic immunohistochemical profile of BL is positive for BCL6, CD10, and other B-cell antigens without expression of BCL2, [37][38][39][40] although BL with positive BCL2 staining can still be diagnosed if other characteristic features of BL are present. Expression of CD38 and B-cell antigens, including CD20, CD79a, and CD79b, is generally strong in BL.…”

mentioning

confidence: 99%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity.Objectives.-To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells.Data Sources.-Published and PubMed-indexed English literature was reviewed.Conclusions.-Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1 þ large B-cell lymphoma.

show abstract

“…Flow cytometry will often show strong expression of CD38, a reflection of the high proliferative cell fraction in BL. 67,94 A classic immunophenotype can accurately diagnose BL in approximately 94% of cases (CD20…”

Section: Primary Effusion Lymphomamentioning

confidence: 99%

“…94 In situ staining for EBV (EBER) will be positive in some cases, more often in those associated with immunosuppression.…”

Section: Primary Effusion Lymphomamentioning

confidence: 99%

Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas

O’Malley¹,

Auerbach²,

Weiss³

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context Diffuse large B-cell lymphoma is the most commonly diagnosed subtype of lymphoma worldwide. The current World Health Organization (WHO) classification includes several subtypes, based on a combination of clinical, immunohistochemical, and genetic differences. Immunohistochemical staining is essential in evaluating diffuse large B-cell lymphoma and many related large B-cell lymphomas and aggressive B-cell lymphomas. Objective To address different immunohistochemical features used for identification, subclassification, prognosis and in some cases, therapy, of diffuse large B-cell lymphoma and related lymphomas. Data Sources The information outlined in this review article is based on our experiences with routine cases, on the current WHO classification of hematopoietic and lymphoid tumors, and on a review of English-language articles published throughout 2014. Conclusions Features and diagnostic criteria of diffuse large B-cell lymphoma, aggressive variants of B-cell lymphomas, including Burkitt lymphoma and “double-hit” lymphomas, are discussed. Identification of cell of origin (germinal center type versus activated B-cell type) is discussed at length. Finally, practical approaches for diagnosis are discussed.

show abstract

Diagnosis of Burkitt lymphoma using an algorithmic approach – applicable in both resource‐poor and resource‐rich countries

Cited by 58 publications

References 18 publications

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas

Contact Info

Product

Resources

About